There are currently 167 active clinical trials seeking participants for Lung Cancer research studies. The states with the highest number of trials for Lung Cancer participants are Ohio, California, Illinois and Michigan.
The MyLungHealth Study Protocol: Engaging Patients to Enable Interoperable Lung Cancer Decision Support at Scale
NCT06338592
Recruiting
Early lung cancer screening (LCS) through low-dose computed tomography (LDCT) is crucial but underused due to various barriers, including incomplete or inaccurate patient smoking data in the electronic health record and limited time for shared decision-making. The objective of this trial is to investigate a patient-centered intervention, MyLungHealth, delivered through the patient portal. The intervention is designed to improve LCS rates through increased identification of eligible patients and... Read More
Gender:
ALL
Ages:
Between 50 years and 79 years
Trial Updated:
06/05/2024
Locations: NYU Langone Health, New York, New York +1 locations
Conditions: Lung Cancer, Lung Neoplasms/Diagnosis
Register for Updates
DNA Evaluation of Fragments for Early Interception - Lung Cancer Training Study (DELFI-L101 Study)
NCT04825834
Recruiting
The primary objective of this study, DELFI-L101, is to train and test classifiers for lung cancer detection using the DELFI assay and other biomarker and clinical features.
Gender:
ALL
Ages:
50 years and above
Trial Updated:
06/05/2024
Locations: Memorial Sloan Kettering Cancer Center, New York, New York +1 locations
Conditions: Lung Cancer, Head and Neck Cancer, Esophageal Cancer, Bladder Cancer, Kidney Cancer, Stomach Cancer, Colorectal Cancer, Pancreas Cancer, Liver Cancer, Skin Cancer
Register for Updates
Collecting and Analyzing Tissue Samples From Patients Undergoing Surgery for Non-Small Cell Lung Cancer
NCT00897117
Recruiting
RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that may occur in RNA and identify biomarkers related to cancer. PURPOSE: This research study is collecting and analyzing lung tissue samples from patients undergoing surgery for non-small cell lung cancer.
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
05/21/2024
Locations: Dan Rudy Cancer Center at Saint Thomas Hospital, Nashville, Tennessee +2 locations
Conditions: Lung Cancer
Register for Updates
A Randomised Controlled Trial to Evaluate the Impact of Complement Theory's Live 1:1 Exercise Coaching and Personalised Digital Application on Cancer Survivors' Cost of Care
NCT06397651
Recruiting
A Decentralized, Double-blinded, Randomized, 18 month, Parallel-group, Superiority Study to evaluate the impact of Complement Theory's Live 1:1 Exercise Coaching and Personalized Digital Application on Cancer Survivors' Cost of Care
Gender:
ALL
Ages:
Between 21 years and 64 years
Trial Updated:
05/15/2024
Locations: Complement Theory Inc., Dover, Delaware
Conditions: Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer, Other Cancer
Register for Updates
Assessment of a Radiomics-based Computer-Aided Diagnosis Tool for Pulmonary nodulES
NCT05968898
Recruiting
This is a pragmatic clinical trial that will study the effect of a radiomics-based computer-aided diagnosis (CAD) tool on clinicians' management of pulmonary nodules (PNs) compared to usual care. Adults aged 35-89 years with 8-30mm PNs evaluated at Penn Medicine PN clinics will undergo 1:1 randomization to one of two groups, defined by the PN malignancy risk stratification strategy used by evaluating clinicians: 1) usual care or 2) usual care + use of a radiomics-based CAD tool.
Gender:
ALL
Ages:
Between 35 years and 89 years
Trial Updated:
05/13/2024
Locations: Penn Medicine University City, Philadelphia, Pennsylvania +2 locations
Conditions: Lung Cancer, Pulmonary Nodule, Solitary
Register for Updates
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
NCT03175224
Recruiting
To assess: * efficacy of APL-101 as monotherapy for the treatment of NSCLC harboring MET Exon 14 skipping mutations, NSCLC harboring MET amplification, solid tumors harboring MET amplification, solid tumors harboring MET fusion, primary CNS tumors harboring MET alterations, solid tumors harboring wild-type MET with overexpression of HGF and MET * efficacy of APL-101 as an add-on therapy to EGFR inhibitor for the treatment of NSCLC harboring EGFR activating mutations and developed acquired resis... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/08/2024
Locations: Loma Linda University Medical Center, Loma Linda, California +90 locations
Conditions: Advanced Cancer, Renal Cancer, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, NSCLC, Lung Cancer, Brain Tumor, Glioblastoma Multiforme, Solid Tumors, EGFR Gene Mutation, MET Amplification, HGF, Thyroid Cancer, Pancreatic Cancer, Colon Cancer, MET Alteration, MET Fusion, Exon 14 Skipping
Register for Updates
Adapting and Testing a Novel Self-Compassion Intervention to Reduce Lung Cancer Stigma
NCT06191939
Recruiting
The goal of this pilot clinical trial is to test a disease-tailored, mindfulness-based intervention (Mindful Self-Compassion for Lung Cancer; MSC-LC) in adults diagnosed with lung cancer who are experiencing stigma. The current project seeks to: * Evaluate preliminary evidence for the feasibility, acceptability, and preliminary efficacy of MSC-LC in reducing stigma for adults with lung cancer, compared to a waitlist control condition * Elicit interventional impact not captured through quantitat... Read More
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
05/07/2024
Locations: Loyola Marymount University, Los Angeles, California
Conditions: Lung Cancer
Register for Updates
Cardiopulmonary Monitoring in Lung Cancer Patients Receiving Combined Thoracic Radiotherapy and Immunotherapy
NCT06410300
Recruiting
The overall purpose of this study is to evaluate cardiopulmonary toxicity in patients with lung cancer (NSCLC or SCLC) undergoing combined thoracic radiotherapy ± chemotherapy and immunotherapy through timed monitoring and blood sample collection and to identify correlative biomarkers for predicting cardiopulmonary adverse events.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/07/2024
Locations: University of Missouri - Ellis Fischel Cancer Center, Columbia, Missouri +2 locations
Conditions: Lung Cancer
Register for Updates
Studying Tumor Tissue Samples and Blood Samples to Learn More About DNA Changes in Patients With Lung Cancer
NCT00899405
Recruiting
RATIONALE: Studying samples of tumor tissue and blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. PURPOSE: This laboratory study is looking at tumor tissue samples and blood samples to learn more about DNA changes in patients with lung cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/06/2024
Locations: University of California Davis Cancer Center, Sacramento, California
Conditions: Lung Cancer
Register for Updates
Adaptive Symptom Self-Management Immunotherapy Study
NCT05715255
Recruiting
The use of immune checkpoint inhibitors (ICIs), alone or in combination with other cancer treatments is increasing dramatically with immune-related adverse events (irAEs) common (90%) during ICI treatment. Most irAEs are symptomatic and symptom self-management with timely reporting of moderate or severe symptoms to health care providers (HCPs) may reduce irAE severity by early recognition and management, resulting in fewer treatment interruptions and unscheduled health services.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/12/2024
Locations: University of Arizona Cancer Center, Tucson, Arizona +1 locations
Conditions: Breast Cancer, Colon Cancer, Lung Cancer, Skin Cancer, Rectum Cancer
Register for Updates
ATATcH Alternating Treatment Plans for Advanced Cancer
NCT05358548
Recruiting
The purpose of the research is to evaluate a new schedule of alternating cycles of induction chemoimmunotherapy (chemotherapy plus pembrolizumab) and immunotherapy (pembrolizumab) alone for the initial treatment of patients with advanced lung or head and neck cancers.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/09/2024
Locations: Trinitas Hospital and Comprehensive Cancer Center, Elizabeth, New Jersey +10 locations
Conditions: Head and Neck Cancer, Lung Cancer
Register for Updates
Increasing Equity in Lung Cancer Screening
NCT06360822
Recruiting
The overall objective of this mixed methods study is to: 1) Refine the Emergency Department Lung Cancer Screening (ED-LCS) intervention using qualitative interviews among key stakeholders; 2) pilot test the ED-LCS intervention evaluating the intervention efficacy, acceptability, and feasibility; and 3) provide an in-depth description of stakeholders' experiences with the ED-LCS intervention for future refinement.
Gender:
ALL
Ages:
Between 50 years and 80 years
Trial Updated:
04/08/2024
Locations: Eskenazi Health, Indianapolis, Indiana
Conditions: Lung Cancer
Register for Updates